Contents

Contents		Page No.
List of Tables		xiv
List of Figures		xv-xvi
List of Abbreviations and Symbols		xvii-xx
Preface		xxi-xxiii
1.	**Introduction**	**01-11**
2.	**Literature Review**	**12-49**
2.1	Obesity	12
2.2	Epidemiology of Obesity	12
2.3	Pathogenesis of Obesity	16
2.4	Management of Obesity	17
2.5	Complications of Obesity	19
2.6	Adipose tissues	21
2.6.1	WAT	21
2.6.2	BAT	22
2.7	Adipokines	23
2.8	Dysfunctions induced in adipose tissue in Obesity	26
2.8.1	Adipose tissue expansion	28
2.8.2	Adipose tissue inflammation	28
2.8.3	Disturbed adipokine profile	30
2.8.4	Adipose tissue oxidative stress	33
2.8.5	Mitochondrial dysfunction	34
2.9	Obesity and Insulin resistance	36
2.10	Obesity and NAFLD	38
2.11	AMPK	40
2.12	Need and scope of repurposing of the US-FDA approved drugs	44
2.13	Sitagliptin	45
2.13.1	Efficacy of Sitagliptin on the metabolic syndrome parameters from the clinical observations	47
2.13.2	The dose of Sitagliptin selected for the experimental design	48
2.13.3	Safety of Sitagliptin	48

3.	**Objectives**	**50**
4.	**Materials and Methods**	**51-80**
4.1	Ethical Approval	51
4.2	Drugs, chemicals, antibodies, and ELISA kits	51
4.3	Equipment and Software	54
4.4	Animal husbandry	56
4.5	Experimental designs	57
4.5.1	Experimental design for selection of Obese and insulin resistant animals	57
4.5.2	Experimental design for Objective I	58
4.5.3	Experimental design for Objective II	59
4.5.4	Experimental design for Objective III	60
4.6	Methods	61
4.6.1	Preparation of Control diet and High-fat diet	61
4.6.2	Induction of obesity and metabolic syndrome in mice	62
4.6.3	Experimental groups	62
4.6.4	Serum and tissue preparation	63
4.6.5	Estimation of body weight, organ weight, and cumulative food intake	63
4.6.6	Biochemical estimations	63
4.6.6.1	Estimation of Fasting blood glucose (FBG) and OGTT	63
4.6.6.2	Estimation of Insulin tolerance test (ITT), fasting serum insulin (FSI) and Homeostasis model of insulin resistance (HOMA-IR)	64
4.6.6.3	Estimation of Serum lipid profile, ALT, and AST levels	64
4.6.6.4	Estimation of serum Leptin and Adiponectin	65
4.6.6.5	Estimation of serum free fatty acids, uric acid, and GLP-1 level	65
4.6.7	Estimation of hepatic lipid and hepatic oxidative stress	65
4.6.8	H & E staining	66
4.6.9	Estimation of IL-6, TNF-α, and MCP-1 levels in eWAT	67
4.6.10	Estimation of oxidative stress in eWAT and iBAT	68
4.7	Western blotting	68
4.8	Reverse transcriptase-Polymerase Chain reaction (RT-PCR)	74
4.9	Statistical analysis of Data	80

5.	**Results**	**81-112**
5.1	To study the effect of Sitagliptin on metabolic syndrome, fatty liver and hepatic oxidative stress in a high-fat diet-induced animal model of obesity (Objective I)	81
5.1.1	Effect of Sitagliptin on body weight, weight gain, and FBG level in obese mice	82
5.1.2	Effect of Sitagliptin on cumulative food intake, liver weight index and visceral fat index in obese mice	83
5.1.3	Effect of Sitagliptin on OGTT and area under the curve of blood glucose (AUG) in obese mice	84
5.1.4	Effect of Sitagliptin on ITT in obese mice	86
5.1.5	Effect of Sitagliptin on FSI and HOMA-IR in obese mice	87
5.1.6	Effect of Sitagliptin on lipid profile in obese mice	88
5.1.7	Effect of Sitagliptin on serum free fatty acid levels in obese mice	89
5.1.8	Effect of Sitagliptin on ALT and AST levels in obese mice	90
5.1.9	Effect of Sitagliptin on serum leptin and adiponectin levels in obese mice	91
5.1.10	Effect of Sitagliptin on serum uric acid and GLP-1 levels in obese mice	92
5.1.11	Effect of Sitagliptin on hepatic fat content in obese mice	93
5.1.12	Effect of Sitagliptin on hepatic oxidative stress in obese mice	94
5.1.13	Hepatic histopathological evaluation	95
5.2	To analyze the potency of Sitagliptin on white adipose tissue inflammation, adiponectin expression and hepatic fatty acid metabolism in experimentally induced obese mice with focus on AMPK signaling (Objective II).	97
5.2.1	Effect of Sitagliptin on pro-inflammatory cytokine levels in eWAT in obese mice	97
5.2.2	eWAT histopathological evaluation	98
5.2.3	Effect of Sitagliptin on hepatic and eWAT Adiponectin mRNA expression in obese mice	98
5.2.4	Effect of Sitagliptin on hepatic AMPK and ACC phosphorylation in obese mice	99
5.2.5	Effect of Sitagliptin on hepatic mRNA expression of fatty acid metabolism genes in obese mice	101

5.3	To investigate the effect of Sitagliptin on oxidative stress and mitochondrial biogenesis markers in white and brown adipose tissues in metabolically compromised obese mice (Objective III).	103
5.3.1	Effect of Sitagliptin on WAT and BAT weight in metabolically compromised obese mice	103
5.3.2	Effect of Sitagliptin on oxidative stress in eWAT in metabolically compromised obese mice	104
5.3.3	Effect of Sitagliptin on oxidative stress in iBAT in metabolically compromised obese mice	105
5.3.4	iBAT histopathological evaluation	107
5.3.5	Effect of Sitagliptin on eWAT P-AMPK levels in metabolically compromised obese mice	107
5.3.6	Effect of Sitagliptin on iBAT P-AMPK levels in metabolically compromised obese mice	109
5.3.7	Effect of Sitagliptin on mRNA expression of thermogenesis and mitochondrial biogenesis markers in eWAT in metabolically compromised obese mice	110
5.3.8	Effect of Sitagliptin on mRNA expression of thermogenesis and mitochondrial biogenesis markers in iBAT in metabolically compromised obese mice	111
6.	**Discussion**	**113-132**
6.1	To study the effect of Sitagliptin on metabolic syndrome, fatty liver and hepatic oxidative stress in high-fat diet induced animal model of obesity (Objective I)	113
6.2	To analyze the potency of Sitagliptin on white adipose tissue inflammation, adiponectin expression and hepatic fatty acid metabolism in experimentally induced obese mice with focus on AMPK signaling (Objective II)	124
6.3	To investigate the effect of Sitagliptin on oxidative stress and mitochondrial biogenesis markers in white and brown adipose tissues in metabolically compromised obese mice (Objective III)	128
7.	**Conclusion**	**133-135**
	References	**136-174**
	Publications	